Cargando…

Glucose and Cell Context-Dependent Impact of BMI-1 Inhibitor PTC-209 on AKT Pathway in Endometrial Cancer Cells

SIMPLE SUMMARY: The insulin/IGF-1/AKT pathway is a key event linking metabolic syndrome with endometrial cancer. It has been found that BMI-1 may also influence the AKT kinase pathway and that increased activity is associated with cancer onset and progression. The aim of our study was to determine t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaczek, Agnieszka, Szustka, Aleksandra, Krześlak, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739103/ https://www.ncbi.nlm.nih.gov/pubmed/36497428 http://dx.doi.org/10.3390/cancers14235947

Ejemplares similares

The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells
por: Mayr, Christian, et al.
Publicado: (2015)

Relationship between polycomb‐group protein BMI‐1 and phosphatases regulating AKT phosphorylation level in endometrial cancer
por: Zaczek, Agnieszka, et al.
Publicado: (2019)

Bmi1 inhibitor PTC-209 promotes Chemically-induced Direct Cardiac Reprogramming of cardiac fibroblasts into cardiomyocytes
por: Testa, Gianluca, et al.
Publicado: (2020)

Pharmacological inhibition of Bmi1 by PTC-209 impaired tumor growth in head neck squamous cell carcinoma
por: Wang, Qiong, et al.
Publicado: (2017)

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
por: Bolomsky, Arnold, et al.
Publicado: (2016)

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
por: Alzrigat, Mohammad, et al.
Publicado: (2017)

PTC-209 Anti-Cancer Effects Involved the Inhibition of STAT3 Phosphorylation
por: Sulaiman, Shahrazad, et al.
Publicado: (2019)

Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma
por: Maeda, Aya, et al.
Publicado: (2018)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Off-target effect of the BMI1 inhibitor PTC596 drives epithelial-mesenchymal transition in glioblastoma multiforme
por: Flamier, Anthony, et al.
Publicado: (2020)

Preclinical activity of the novel B‐cell‐specific Moloney murine leukemia virus integration site 1 inhibitor PTC‐209 in acute myeloid leukemia: Implications for leukemia therapy
por: Nishida, Yuki, et al.
Publicado: (2015)

CHD4 Predicts Aggressiveness in PTC Patients and Promotes Cancer Stemness and EMT in PTC Cells
por: Pratheeshkumar, Poyil, et al.
Publicado: (2021)

The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells
por: Nishida, Y, et al.
Publicado: (2017)

Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells
por: Forma, Ewa, et al.
Publicado: (2018)

Expression of GLUT1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers
por: Krzeslak, Anna, et al.
Publicado: (2012)

Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin-dependent kinase inhibitors
por: Kubczak, Małgorzata, et al.
Publicado: (2019)

TET3- and OGT-Dependent Expression of Genes Involved in Epithelial-Mesenchymal Transition in Endometrial Cancer
por: Ciesielski, Piotr, et al.
Publicado: (2021)

MAD-X PTC Integration
por: Schmidt, Frank, et al.
Publicado: (2005)

Efficacy of the novel tubulin polymerization inhibitor PTC‐028 for myelodysplastic syndrome
por: Zhong, Cheng, et al.
Publicado: (2020)

The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells
por: Nagai, Yurie, et al.
Publicado: (2021)

Advances in MAD-X using PTC
por: Skowronski, P K, et al.
Publicado: (2007)

PTC_py-ORBIT - Release & Benchmarking
por: HOLMES, Jeffrey A
Publicado: (2014)

ret/PTC-1 expression alters the immunoprofile of thyroid follicular cells
por: Denning, Karen, et al.
Publicado: (2008)

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAF(V600E) Mutation Status and Other Prognostic Factors
por: Czarniecka, Agnieszka, et al.
Publicado: (2015)

At R209
por: CERN PhotoLab
Publicado: (1976)

At R209
Publicado: (1977)

At R209
Publicado: (1977)

At R209
Publicado: (1977)

At R209
Publicado: (1977)

At R209
Publicado: (1977)

At R209
por: CERN PhotoLab
Publicado: (1976)

Properties of $^{209}_{84}$Po$_{125}$ as observed in the decay of $^{209}$At
por: Alpsten, M, et al.
Publicado: (1971)

Obesity alters the mouse endometrial transcriptome in a cell context-dependent manner
por: Wilson, Mike R., et al.
Publicado: (2022)

Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin
por: Pant, Alok, et al.
Publicado: (2012)

Identification of Potential BRAF Inhibitor Joint Therapy Targets in PTC based on WGCAN and DCGA
por: Han, YaLi, et al.
Publicado: (2021)

Molecular Targets of Natural Compounds with Anti-Cancer Properties
por: Kubczak, Małgorzata, et al.
Publicado: (2021)

Akt regulates Progesterone Receptor B dependent transcription and angiogenesis in endometrial cancer cells
por: Lee, Irene I., et al.
Publicado: (2016)

Discovery of small-molecule inhibitors targeting the ribosomal peptidyl transferase center (PTC) of M. tuberculosis
por: Tam, Benjamin, et al.
Publicado: (2019)

A study to evaluate association of nuclear grooving in benign thyroid lesions with RET/PTC1 and RET/PTC3 gene translocation
por: Ashwini, Basavaraj Rangalakshmi, et al.
Publicado: (2023)

Expression, Localization, and Phosphorylation of Akt1 in Benign and Malignant Thyroid Lesions
por: Krześlak, Anna, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fgacpcsm1d2fv2nvji1d7frn23